PATENT CLAIM ANALYSIS

Application Number: 15870308
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "04400A"]

Abstract:
The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Claim (Index 6):
The antisense oligomer according to  claim 1 , consisting of the nucleotide sequence shown by any one selected from the group consisting of the 160th to the 181st, the 159th to the 181st, the 160th to the 180th, the 159th to the 180th, the 157th to the 178th, the 156th to the 178th, the 155th to the 178th, the 156th to the 177th, the 155th to the 177th, the 156th to the 176th, the 155th to the 176th, the 157th to the 175th, the 156th to the 175th, and the 155th to the 175th nucleotides of SEQ ID NO: 5.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 86.0
- Lexical Diversity: 1.75758
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14368307', '15339069', '13819520', '15619996', '14615504']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.91991113600244
- 35 USC 102 Novelty (BERT): 0.6262890825087921
- Combined Prediction Score: 0.8905489306530753
- Mean Citation Score: 750.7423379999999
- Max Citation Score: 937.6796
- Similarity Product: 540.3696307029962

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test